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Abstract: Tipranavir, a non-peptidic protease inhibitor which shows in vitro efficacy against some HIV-1-resistant 
strains, can be used in salvage therapies for multi-experienced HIV patients due to its peculiar resistance profile including 
21 mutations at 16 protease positions according to International AIDS Society (IAS). Other genotypic scores, however, 
which attribute a different weight to single amino-acid substitutions, have been recently proposed. To validate the clinical 
utility of four different genotypic scores for selecting tipranavir responders, the baseline resistance pattern of 176 HIV 
heavily experienced patients was correlated with virological success (HIV-RNA<50 copies/ml) after 24 weeks of a new 
treatment based on tipranavir/ritonavir. Virological suppression after 24 weeks was reached by 42.5% of patients. With 
univariate analysis, genotypic scores were all associated with outcome but showed a low accuracy with ROC analysis, 
with the weighted score (WS) by Scherer et al. demonstrating the best performance with an AUC of 68%. Only 52% of 
patients classified as susceptible (WS3) responded to the new therapy. The following variables were significantly 
associated (p<0.05) to failure with multivariate analysis: WS, log peak of HIV-RNA, IAS mutations: L33F, I54AMV, 
Q58E, and non-IAS mutation: N37DES. On the contrary, the use of T20 in T20-naïve patients and the V82AFSI and 
F53LY non-IAS mutations were associated with virological success. The study suggests that even if the “weighted” scores 
are able to interpret correctly the antiretroviral resistance profile of multi-experienced patients, it is difficult to individuate 
a cut-off which can be easily applied to this population for discriminating responders. 
Keywords: Antiretrovirals, protease inhibitors, genotypic resistance, tipranavir. 
INTRODUCTION 
 In the HAART era, a wide antiretroviral resistance, 
particularly if extended to all drug classes, is still associated 
with a poor clinical outcome and represents a risk-marker for 
disease progression and mortality [1]. However, the results 
of recent trials with new boosted protease inhibitors (PIs), 
such as tipranavir/ritonavir (TPV/r) [2-4] and darunavir/ 
ritonavir [5] which demonstrate efficacy as salvage therapy 
in a percentage of patients ranging from 20% to 60%, have 
permitted specialists to update the guidelines for treatment of 
highly antiretroviral-experienced HIV-infected patients [6]. 
Virological suppression is now considered possible also for 
multi-experienced patients when treated with at least two 
active drugs from different classes, eventually including 
entry inhibitors, integrase inhibitors and, in the near future, 
other drugs in advanced stages of development. 
 
 
*Address correspondence to this author at the Clinic of Infectious Diseases, 
University of Foggia, v.le L. Pinto, 1 – 71100 Foggia, Tel/Fax: +39 0881 
732215; E-mail: a.saracino@medicina.unifg.it 
 The results of these phase II/III clinical trials, 
nevertheless, should always be evaluated in the context of 
clinical practice with regard to drug effectiveness and 
predictive power for genotypic resistance patterns, thereby 
avoiding a selection bias due to inherent systematic 
differences between the trial population and the general 
patient population. This is particularly true for tipranavir, a 
PI which shows in vitro activity against some PI-resistant 
HIV-1 strains [7, 8], and whose resistance profile seems to 
require multiple protease mutations to determine a reduced 
susceptibility. In fact, while four main mutations in the 
protease gene (at positions 33, 82, 84 and 90) were originally 
associated with TPV/r resistance, a more recent large 
database analysis has revealed that at least 21 mutations at 
16 positions in the protease gene (L10V, I13V, K20M/R/V, 
L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, 
H69K, T74P, V82L/T, N83D, and I84V) are involved in 
determining TPV/r loss of susceptibility, some of which are 
not associated with resistance to any other PIs [9, 10]. Some 
perplexities regarding the validity of the current TPV/r score 
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(TS) [9] have been advanced in recent reports [11] 
1,2 
which 
underlined the importance of attributing a different weight to 
diverse amino acid variants for each protease positions, with 
some substitutions improving rather than reducing the 
response to TPV/r. In an initial report by Parkin et al.
 1
, the 
relationship between genotypic TPV/r resistance-associated 
mutations and the fold-change in phenotypic susceptibility to 
the drug in clinical isolates was analyzed and several 
additional mutations were identified as associated with fold 
change either significantly higher or lower than expected; 
therefore, a revised TPV/r score (PS) assigning a variable 
weighting to different mutations has been proposed. When 
studying the correlation between genotype and virological 
response in a multi PI-experienced patient cohort, Marcelin 
et al. [11] also suggested a different score (MS) associating 
some mutations with failure, and others (53L/W/Y) with 
response to TPV/r. 
 Lastly, a TPV/r-weighted score (WS) 
2 
has been recently 
developed using data from the RESIST trials in which only 
mutations I47V, I54AVM, Q58E, T74P, V82LT, and N83D 
showed the greatest weights in influencing virological 
failure, while other mutations (L24I, I50LV, I54L, L76V), 
not included in the current TPV/r score, were associated to 
an increased TPV/r susceptibility.
 
 In the present study, the protease resistance pattern at 
baseline was correlated with virological success (HIV-
RNA<50 copies/ml) after 24 weeks of treatment in a 
population of 176 HIV patients enrolled in the Italian 
Expanded Access Program for Tipranavir, with the aim of 
evaluating the clinical applicabiliy of the above mentioned 
TPV/r genotypic scores for discriminating possible TPV/r 
responders. 
PATIENTS AND METHODS 
Study Population 
 A total of 176 HIV-1 infected patients who were enrolled 
in the Italian Early Access Program (EAP BI 1182.16 study) 
in the period between November 2004 and January 2006 
were administered a tipranavir/ritonavir (TPV/r)-based 
regimen. The study was reviewed and approved by the 
Independent Ethics Committee of each participating Center. 
Only patients for whom a baseline genotypic resistance 
profile was available were included in the analysis. 
According to the TPV/r EAP inclusion criteria, patients were 
>18-years old, previously treated with all three antiretroviral 
classes including at least two PI-based regimens, and failing 
or intolerant to other approved antiretroviral treatments. The 
use of other investigational drugs within 30 days prior to 
TPV/r initiation and baseline hepatic impairment (AST 
and/or ALT values more than three times the upper normal 
limit) represented a criteria for exclusion. All patients 
provided a written informed consent. 
                                                
1Parkin L, Chappey C. Protease mutations associated with a higher or lower 
than expected tipranavir (TPV) susceptibility based on the TPV mutation 
score. Presented at: XIII Conference on Retrovirus and Opportunistic 
Infections; 5-8 February 2006; Denver, CO, USA. Abstract 637. 
2Scherer J, Boucher CA, Baxter JD, et al. Improving the prediction of 
virologic response to tipranavir: the development of a tipranavir weighted 
score. Presented at: at: XI European AIDS Conference Society; 24 - 27 
October 2007; Madrid, Spain. Poster P3.4/07. 
Methods 
 CD4+ cell counts were performed locally using standard 
flow cytometry. Plasma HIV-1 RNA was assessed in each 
centre participating in study by means of branched DNA 
(Versant RNA, version 3.0 [Bayer]), Amplicor (Monitor test, 
version 1.5 [Roche Diagnostics]) or nucleic acid sequence–
based amplification (Nuclisens, version 2.1 [Bio-Merieux]); 
the highest limit of HIV-RNA detection accepted was 50 
copies. 
 Baseline HIV-1 genotyping test was also performed 
locally using either the 6.0 and 7.0 TrueGene kit (Bayer) or 
the Viro-Seq kit (Abbott). The optimized background 
regimen (OBR) was selected by the investigators based on 
genotypic data. The Sequence Analysis Program of the 
Stanford HIV RT and Protease Sequence Database 
(http://hivdb.stanford.edu/hiv/) (version 4.1.9) was used for 
the interpretation of mutational profiles. No resistance 
testing was performed for T-20, which was included in 
the new regimen based on patient clinical history and 
physician judgement. 
 HIV-1 pol sequences (GenBank accession numbers 
EU007912-EU008077) were then retrospectively collected 
by the Coordinating Center and compared to a reference 
sequence of HIV-1 subtype B with the use of the free online 
Sequence Analysis Program (http://hivdb.Stanford.edu) 
which also provided a subtype assignment; genotypic data 
were reported as amino acid substitutions with respect to the 
consensus B. The substitutions at positions associated with 
TPV/r drug-resistance according to the IAS–USA list [10]
 
were all included in the analysis; the amino acid variants 
other than those indicated by IAS were analyzed separately. 
For the additional positions within the protease domain, all 
the amino acid variants differing from the consensus were 
considered as mutations, but only those detected in at least 
10% of patients were included in the analysis. 
 Four different genotypic scores: original TPV/r score 
(TS) [9], Scherer score (WS) 
2
, Parkin score (PS) 
1
 and 
Marcelin score (MS) [11] were calculated. 
 For TS [9], one point was assigned for the presence of 
each of the following mutations: L10V, I13V, K20M/R/V, 
L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, 
H69K, T74P, V82L/T, N83D, and I84V (score range: 0 to 
+16). 
 For WS 
2
, the score was calculated as follows: L10V= 1, 
I13V= 0, K20M/R/V= 0, L33F= -2, E35G= 0, M36I= 2, 
K43T= 2, M46L= 1, I47V= 6, I50LV= -4, I54A/M/V= 3, 
I54L= -7, Q58E= 5, H69K= 0, T74P= 6, V82L/T= 5, N83D= 
4, and I84V= 2 (score range: -13 to +37). 
 For PS 
1
, the following score system was applied: 
L10VI= 0.5, V11L = 1, I13V= 0.5, K20M/V= 1, K20R= 0.5, 
L24I = -1, D30N=-1, V32I =1, L33F= 1, E35G= 1, M36I= 1, 
K43T= 1, M46IL= 0.5, I47V= 2, I50LV= -1, I54M/V= 1, 
I54L= -1, Q58E= 1, H69K= 1, A71L= 1, G73T= 1, T74P= 1, 
L76V= -1, V82I = -1, V82L= 1, V82T= 2, N83D= 1, I84V= 
2, L89V= 1, and L90M= 0.5 (score range : -6 to +24.5). 
 Finally, for MS
 
[11] one point was assigned to mutations: 
36I/L/V, 58E, 69I/K/N/Q/R/Y and 89I/M/R/T/V, while a -1 
value was attributed to the 53L/W/Y mutation (score range: -
1 to +4). 
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 Antiretroviral drug resistance was also evaluated using 
the Virtual Phenotype
TM
-LM (Virco) (VP). At the time of 
analysis, the clinical cut-off values for tipranavir were based 
on treatment response in patients enrolled in the RESIST 
trials [2-4]; a maximum response was foreseen for isolates 
with a predicted fold-change in IC50 below the lower clinical 
cut-off (=1.2), a reduced response for those with a fold 
change between the lower and the upper clinical cut-off 
(=5.4), while a minimal response was predicted for isolates 
with a fold change above 5.4. 
Statistical Analysis 
 Treatment response was defined as a confirmed HIV-1 
load <50 copies/ml at week 24. Analyses were performed on 
an intention-to-treat basis (all patients who started the TPV/r 
regimen were included). 
 Descriptive statistics were produced for demographic, 
clinical, virological and immunological characteristics of all 
cases and data are reported as median and interquartile range 
(IQR). Logistic regression was applied to analyze the 
association between virological response and clinical and 
virological variables. The variables included: age, gender, 
risk factor for the acquisition of HIV-1 infection, CDC 
staging, HCV and HBV co-infections, HIV-1 subtype, nadir 
of CD4 cell count, peak of HIV-RNA in the patient’s history, 
prior virological suppression after HAART treatment, 
baseline CD4 count, baseline log10 HIV-RNA, number of 
previous antiretroviral regimens, previous exposure to 
antiretroviral drugs, previous treatment with enfuvirtide, 
number of active drugs in the new regimen according to 
Virtual Phenotype
TM
-LM, total number of IAS PI-resistance 
associated mutations, predicted fold-change in TPV/r 
susceptibility according to VP, TS, WS, PS, MS, and single 
protease point mutations. 
 Mutations detected in >10% of patients with a p<0.2 
value were retained for further analysis. A stepwise 
estimation model with backward procedure was used to 
select the set of mutations and clinical variables most 
strongly associated with virological response [12]. 
 The prediction accuracy of each genotypic score was 
evaluated using Receiver Operating Characteristic (ROC); 
adjusted values for background drug activity (BAS, 
Background Activity Score: predicted viral load reduction by 
the OBR) 
3 
were reported as well. 
 Data analysis was performed with STATA statistical 
package (release 9.0, 2006, Stata Corporation, College 
Station, Texas, USA). 
RESULTS 
Patient Characteristics 
 Baseline characteristics of patients enrolled in the study 
are shown in (Table 1). In addition to TPV/r, the new 
therapy included a NNRTI in 15/176 patients (8.5%), and 
enfuvirtide (with or without NNRTIs) in 99/176 patients 
(56.2%), 71 of whom were enfuvirtide-naïve and 28 were 
                                                
3 Hall DB, Baxter JD, Shapiro J, et al. Linear modeling to estimate the 
contribution of each drug component of the regimens of highly treatment-
experienced patients in RESIST. Presented at: at: XI European AIDS 
Conference Society; 24 - 27 October 2007; Madrid, Spain. Poster P4.3/71. 
enfuvirtide-experienced. The median number of baseline IAS 
PI-resistance-associated mutations was 15 (IQR: 11-19); the 
median number of IAS TPV/r associated mutations was four 
(IQR: 2–5). The median and range values for each genotypic 
score in our population are also indicated. Fig. (1) presents 
the frequency of baseline protease mutations in our 
population. Median BAS was 0.75 log (0.25 - 1). 
Treatment Efficacy and Predictors of Virological 
Response 
 Overall, 139/176 patients completed the 24 week 
treatment follow-up. A total of 37/176 patients (21%) 
interrupted TPV/r therapy for the following reasons: 
immuno-virological failure and/or clinical impairment 
(36%), intolerance to TPV/r (36%), and non-adherence 
(11%). Four patients died during the follow-up, one of whom 
with an AIDS-related malignancy and the remaining three 
patients for non-AIDS-related events (lung cancer, drug 
overdose, and accidental death, respectively). A total of 
61/159 patients (38.4%) at week 12 and 59/139 (42.4%) 
patients at week 24, respectively, showed a pVL of <50 
copies/ml. The median HIV-RNA log10 decrease was –2.0 
(IQR = -3 to -0.3) after 12 weeks and -2.84 (IQR: -3.1 to -
0.3) after 24 weeks. The median absolute CD4 variation was 
60.5 (IQR: 10.5-137) cells at week 12 and 54 (IQR: 5-147) 
cells at week 24. 
Univariate Analysis 
 The variables significantly associated to outcome (p  
0.05) at univariate analysis are reported in Table 2. 
 CDC stage C versus stage A (OR 2.25, 1.19-4.24 95% 
CI, p=0.013) and the peak of HIV-RNA in the patient’s 
history (OR 2.86, 1.55-5.27 95% CI, p=0.001) were 
associated with virological failure at week 24; while de novo 
use of enfuvirtide was correlated with virological success 
(OR 0.52, 0.27-0.97 95% CI, p=0.042). On the contrary, the 
number of active agents in the OBR was not a predictor of 
virological success in our cohort. The I13V and I54A/M/V 
substitutions among the IAS associated mutations, and 
N37DES, Q92K and I93LM among the non-IAS TPV/r 
associated mutations, resulted significantly associated with 
virological failure at week 24 by univariate analysis. 
 The Virtual Phenotype
TM
-LM TPV/r fold-change was 
significantly correlated with both the total number of 
protease mutations (r=0.44, p<0.0001) and the IAS TPV/r 
score (r=0.53, p<0.0001). The predicted fold-change in 
TPV/r susceptibility was also significantly associated to 
virological failure with univariate analysis (OR 1.53, 1.15-
2.05 95% CI, p=0.004). 
 All the TPV/r scores were associated with failure at week 
24, including: TS (OR 1.35, 1.14-1.59 95% CI, p<0.001); 
WS (OR 1.18, 1.09-1.28 95% CI, p<0.001); PS (OR 1.25, 
1.09-1.43 95% CI, p=0.001) and MS, which showed, 
however, a weaker association with the outcome (OR 1.37, 
1.00-1.89 95% CI, p=0.051) compared to the other 
interpretation systems. 
 The accuracy of the scores in predicting the response to 
TPV/r based therapy is shown in Fig. (2); the highest AUC 
value among the scores was obtained by WS (68%). The cut-
off which showed the highest specificity and sensitivity to 
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discriminate between virological responders/non-responders 
was 5 for WS and PS, 4 for TS, 1.5 for VP and 1 for MS. 
 Using the proposed cut-offs for WS
 2
 (3=susceptible; >3 
- 10= partially susceptible, and  10=resistant), a 
virological response was achieved by 52% of susceptible 
patients (n=38/73), 29% of partially susceptible (n=22/75) 
and by 12% of subject classified as resistant (n=3/25). 
Table 1. Baseline Characteristics of 176 PI-Experienced HIV Infected Patients 
 
Total N of pts 176 
Male (%) 141 (80.1%) 
Median (IQR) age (years) 43 (41 - 48) 
Clinical stage C 86 (48.9%) 
Risk factor  
Ex- IVDU 71 (40.3%) 
      Heterosexual 63 (35.8%) 
     Homosexual 36 (20.5%) 
Unknown 6 (3.4%) 
HCV-Ab + 61 (38%) 
HbsAg + 10 (6.2%) 
Non-B HIV subtype 7 (4.2%) 
Median (IQR) HIV-RNA (log10 copies/ml) 4.8 (4.2 - 5.3) 
Median (IQR) CD4 cell count (cells/mm3) 143.5 (69 - 245) 
Pts with a CD4 nadir <200 159 (90.8%) 
Median (IQR) CD4 nadir (cells/mm3) 47 (16 - 116) 
History of prior virological suppression 71 (44%) 
Median(IQR) N of prior ARV drugs   
                                    NRTIs 6 (5 - 6) 
                                    NNRTIs 1 (1 - 2) 
                                     PIs 4 (3 - 5) 
Enfuvirtide experienced 41 (23.3%) 
Active drugs  2 according to VirtualPhenotypeTM-LM (not including TPV/r and T20) 25 (14%) 
TPV/r prescribed co-treatment  
only NRTI 65 (36.9%) 
+ NNRTI 15 (8,5%) 
+ enfuvirtide 99 (56.2%) 
Median BAS (log10) 0.75 (0.25 - 1)  
Median(IQR) N of PI-resistance associated mutations 15 (11 - 19) 
Median (IQR) N of TPV-associated mutations 4 (2 - 5) 
TPV resistance analysis according to VirtualPhenotypeTM-LM  
                    Maximal response 46% 
                      Reduced respsonse 44% 
                    Minimal repsonse 10% 
TS median (IQR) 4 (0 to 9) 
WS median (IQR) 5 (-7 to +20) 
PS median (IQR) 4 (0 to 14) 
MS median (IQR) 1 (-1 to 3) 
Legend: N: number; pts: patients; IQR: inter quartile range; IVDU: intravenous drug users; ARV: antiretroviral; NRTI: nucleoside retro transcriptase inhibitors; NNRTIs: non-
nucleoside retro transcriptase inhibitors; PIs: protease inhibitors; TPV/r: tipranavir/ritonavir; BAS: Background Activity Score.  
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 The ROC curve adjusted for BAS showed the following 
AUC values for each score: TS 67.6% (95%CI 59.7-75.5), 
VP 61.8 (95%CI 53-70.8), WS 69.8 (95%CI 61.3-78.4), PS 
65.7% (95%CI 57.6-73.8), MS 58.5 (95%CI 49.8-67.3). 
Multivariate Analysis 
 A stepwise estimation model with backward procedure 
was then used to select the set of mutations most strongly 
associated with virological response. The mutations detected 
in >10% of patients and showing a p value <0.2 with 
univariate analysis were entered in the analysis, including: 
L10V, T12KPS, I13V, I15V, G16AE, L19IPV, K20MR, 
L24I, L33F, E34Q, E35D, M36I, N37DES, R41K, K43T, 
M46L, I47V, G48V, F53LY, I54AMV, K55R, Q58E, D60E, 
I62V, L63P, I64LMV, C67FY, H69K, A71VTIL, 
G73ACST, T74AKS, L76V, V77I, V82AFSI, I84V, 
L89IMV, L90M, I93LM. The following mutations were 
selected by the model as significantly (p<0.05) associated to 
failure: L33F (OR 2.86, 1.14-7.22, p=0.026), I54AMV (OR 
5.67, 1.94-16.58, p=0.002), Q58E (OR 3.23, 1.06-9.90, 
p=0.039), among IAS mutations, and N37DES (OR 2.30, 
1.02-5.20, p=0.046) among non IAS mutations. On the 
contrary, V82AFSI (OR 0.20, 0.06-0.66, p=0.007) and 
F53LY (OR 0.24, 0.07-0.78, p= 0.018) among non IAS 
mutations were associated with virological success (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Prevalence of baseline protease mutations in a population of 176 PI-experienced HIV patients. Legend: All mutations included 
in the IAS TPV-score (grey bars) and all other mutations at any position of the protease gene (white bars) showing a prevalence of amino 
acid substitutions with respect to wild type higher than 10% are reported. 
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 A stepwise estimation model with backward procedure 
was also applied to all baseline clinical characteristics 
significantly associated to outcome with univariate analysis 
(Table 2) including WS, which showed the best AUC by 
ROC analysis. The use of T20 in T20 naïve patients (OR 
0.44, 0.20-0.94, p=0.034) was independently associated with 
virological success, while the log peak of HIV-RNA (OR 
2.71, 1.40-5.24, p=0.003) and WS (OR 1.15, 1.05-1.26, p= 
0.004) resulted significantly associated with failure (Table 2). 
DISCUSSION 
 Tipranavir is a non-peptidic protease inhibitor which has 
been proved to be active against some PI-resistant HIV-1 
strains in vitro and could be included in salvage regimens for 
selected multi-experienced HIV patients. Understanding the 
role of predictors in virological response to TPV/r can help 
clinicians to correctly identify patients who might benefit 
from this drug. With this aim, the relationship between 
baseline genotypic resistance and virological response to 
boosted tipranavir was evaluated in a group of PI-
experienced patients. 
 When considering the resistance profile to TPV/r, as is 
well-known, a total of 21 mutations at 16 positions have 
been identified [9] and are currently listed in the IAS tables 
as TPV/r-associated [10],
 
some of which are not involved in 
resistance to other PIs. Other genotypic scores, however, 
Table 2. Univariate and Multivariate Analysis: Variables Associated with Virological Failure at Week 24 
 
Univariate Analysis 
 
OR 95% CI P Value 
CDC stage_C 2.25 1.19 - 4.24 0.013 
Peak of HIV-RNA in the patient’s history 2.86 1.55 - 5.27 0.001 
Use of T20 in T20-naïve pts 0.52 0.27 - 0.97 0.042 
vPt TPV/r fold-change 1.54 1.15 – 2.05 0.004 
Tot N of mutations 1.09 1.03 – 1.16  0.003 
TS (original TPV score) 1.35 1.14 – 1.60 <0.001 
WS (weighted TPV score) 1.18 1.09 - 1.28 <0.001 
PS  (Parkin score) 1.25 1.09 - 1.43 0.001 
MS (Marcelin score) 1.37 1.00 - 1.89 0.051 
IAS TPV/r associated mutations    
I13V 2.08 1.10 – 3.94 0.025 
I54A/M/V 2.42 1.24 – 4.71 0.009 
Other protease mutations    
N37DES 2.19 1.11 – 4.33 0.024 
Q92K 4.81 1.06 – 21.80 0.041 
I93LM 2.25 1.11 - 4.55 0.025 
 MULTIVARIATE ANALYSIS 
 OR 95% CI 
P Value  
 
Use of T20 in T20-naïve pts  0.44 0.20 – 0.94 0.034 
Peak of HIV-RNA in the patient’s history 2.71 1.40 - 5.24 0.003 
WS 1.15 1.05 - 1.26 0.004 
IAS TPV/r associated mutations 
 
   
L33F 2.86 1.14 – 7.22 0.026 
I54AMV 5.67 1.94 – 16.58 0.002 
Q58E 3.23 1.06 – 9.90 0.039 
Other protease mutations    
N37DES 2.30 1.02 – 5.20 0.046 
V82AFSI 0.20 0.06 – 0.66 0.007 
F53LY 0.24 0.07 – 0.78 0.018 
A p value < 0.05 is considered significant (in bold). 
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have been proposed in the last year 
1
 [11] and more recently, 
based on the data from the RESIST trials, a TPV/r-weighted 
score to predict virological response has been developed, in 
which only some mutations (I47V, I54AVM, Q58E, T74P, 
V82LT, and N83D) had greater weights in influencing 
virological failure, while other mutations (L24I, I50LV, 
I54L, L76V), not listed by IAS, were shown to confer an 
increased susceptibility to TPV/r 
2
. Therefore, the 
applicability of four different TPV/r scores of baseline 
genotypic resistance (TS, WS, PS and MS) for predicting 
virological response was evaluated in our population. By 
univariate analysis, all these scores showed a good 
association with outcome. However, none could identify an 
easily applicable cut-off for the complex clinical 
management of our antiretroviral heavily experienced 
patients. When a ROC analysis was performed, in fact, none 
of these scores approached a sufficiently high AUC, even 
when adjusted for BAS, thus showing a reduced accuracy for 
predicting virological failures to TPV/r. Among these tests, 
the WS score proposed by Scherer et al.
2
 demonstrated the 
best performance with an AUC of 68% based on a cut-off of 
5 mutations; the independent association of WS with 
virological failure was also confirmed by the multivariate 
analysis. However, a cut-off of 5 mutations is probably too 
low for this population in which a median number of four 
TPV/r-associated and 15 PI- associated mutations was 
detected at baseline. Moreover, when patients were classified 
according to the proposed cut-offs for WS as susceptible 
(WS 3), partially susceptible (>3 - 10) and resistant ( 
10), while WS could efficiently individuate patients who 
would not respond to a TPV/r based regimen (in fact, 88% of 
patient classified as resistant with a WS >10 did not respond 
to the new therapy in our study), only one half of patients 
classified as susceptible demonstrated a virological response. 
Therefore, additional variables, not considered by genotypic 
scores, such as adherence or toxicities and pharmacokinetics 
aspects, supposedly influence virological success 
independently of baseline genotypes. These results are 
undoubtedly limited by the sample size; however, they also 
highlight the difficulty of predicting response with 
mutational scores which vary considerably with the patient 
populations and statistical methods used to derive them. 
 Furthermore, the TPV/r susceptibility fold-change, as 
predicted by the Virtual Phenotype
TM
-LM, demonstrated a 
good correlation with the baseline number of protease and 
TPV/r-associated mutations in our population and was also 
associated with failure with univariate analysis. Actually, we 
arbitrarily used the Virtual Phenotype
TM
-LM, which 
accurately predicts the real phenotype [13], to quantify the 
TPV/r resistance levels, even if we are aware that the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). ROC curve analysis for the determination of clinical cut-offs. Legend: ROC curve synthetically describes the relationship 
between sensitivity and 100%-specificity: the test is considered more valid when the area under the curve (AUC) approximates 100%; on the 
contrary, the closer the AUC is to 50%, the less valid is the result. The peak of the curve identifies the optimal cut-off to maximize sensitivity 
and specificity. This value corresponded to a cut-off = 5 for WS which showed the largest AUC (68%) from among the TPV/r genotyping 
scores analyzed. 
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accuracy of this approach may be lower for newly-approved 
drugs. 
 Differences among scores were also evidenced by the 
analysis of the association of single mutated positions in the 
protease gene with the virological outcome. Only three 
mutations (L33F, I54AMV, Q58E) among those included in 
the IAS list were associated with virological failure with 
multivariate analysis. The role of mutations I54AMVand 
Q58E in determining resistance to TPV/r is recognized by all 
the proposed genotypic scores. In particular, WS attributes 
one of the highest scores (= 5) to mutation Q58E, which is 
also the only IAS TPV/r-associated mutation retained in the 
MS score attributing it a score of one, as in TS and in PS. It 
is remarkable that Q58E is one of the “novel” protease 
mutations not previously involved in resistance to other PIs. 
Parkin et al. [14],
 
included the Q58E mutation among those 
associated with lopinavir resistance; in addition, this 
mutation is detected more frequently in patients who have 
been treated with more than three PIs, and clusters with 
mutations at positions 10, 46, 54 and 82 [15]
 
which are all 
included in the original TPV/r score. On the contrary, the 
role of mutation L33F is more controversial; only in PS was 
this mutation linked to virological falure, while WS 
considers it as a predictor of virological success; it was 
however, one of the four mutations initially associated to 
TPV/r resistance and its importance is probably 
underestimated by the WS and MS scores. The potential role 
of other protease mutations, not included in the IAS list, on 
virological response to TPV/r was also evaluated in our 
population; in this setting, mutation N37DES resulted 
associated with failure, while mutations F53LY and 
V82AFS, which have been linked to resistance to other drugs 
such as lopinavir/rtv, were identified by the stepwise 
backward analysis as associated with virological success. 
Interestingly, these results confirm the finding of Marcelin et 
al. [11] regarding the beneficial effect of mutation L53LY on 
virological response to TPV/r. 
 In our multi-experienced population, high levels of 
virological response to a new regimen based on TPV/r 
(reaching a pVL >1 log decrease in 62% of cases and <50 
copies/ml in 42% of cases after 24 weeks, respectively) were 
obtained. While clinical variables such as the patient peak 
viral load and a more advanced stage of HIV related disease 
were associated with failure, the inclusion in the combined 
regimen of an agent from a new antiretroviral class, such as 
enfuvirtide, was definitely associated to a better virological 
outcome, as previously demonstrated by the phase II and III 
registration trials [2-4], and probably masked the influence 
of the number of OBR active agents on the virological 
response. 
 In conclusion, this study suggests that the “weighted” 
approach, which attributes a different value to single amino-
acid substitutions in affecting the therapy response, is more 
qualified than unweighted scores to interpret correctly the 
antiretroviral resistance profile of multi-experienced patients, 
even if it was not possible to determine a cut-off which could 
be easily applied for discriminating responders. This 
difficulty also further underlines the importance of validating 
genotypic scores outside of phase II/III clinical trials in order 
to verify their performance in clinical settings. 
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IAS = International AIDS Society 
HAART = Highly Active Antiretroviral Therapy 
PI = Protease Inhibitors 
TPV/r = Tipranavir/ritonavir 
FC = Fold-Change 
TS = Tipranavir Score 
PS = Parkin Score 
MS = Marcelin Score 
WS = Weighted Score 
EAP = Early Access Program 
AST = Aspartate Aminotransferase 
ALT = Alanine Aminotransferase 
T20 = Enfuvirtide 
VP = Virtual Phenotype
TM
-LM, 
IQR = Interquartile Range 
ROC = Receiver Operating Characteristic 
AUC = Area Under Curve 
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